A high expression of stromal PDGFRβ is known to be a poor prognosis marker in several solid tumor types. However, the role of stromal PDGFRβ for non-small cell lung cancer (NSCLC) patients remains unclear. Therefore, we investigated the activation status of PDGFRβ with proximity ligation assay (PLA) by studying the interaction between the receptor and GRB2, one of PDGFRβs downstream signaling molecules. The main aim is in this study is to investigate the activation status of stromal PDGFRβ in NSCLC tissues and look into its clinical relevance for lung cancer patients. Our data revealed that PDGFRβ activation status did not affect overall survival, and was not associated to smoking, sex, age or stage of cancer. PDGFRβ activation status was higher in the histological subgroup of squamous cell carcinoma-patients compared to the adenocarcinoma subgroup. The PDGFRβ activation status showed a clear correlation to the general expression level of PDGFRβ investigated by immunohistochemistry (IHC). The correlation also showed that a high activation status required a high general expression, indicating a specific pipeline.
| Identifer | oai:union.ndltd.org:UPSALLA1/oai:DiVA.org:uu-494977 |
| Date | January 2022 |
| Creators | Hellberg, Louise |
| Publisher | Uppsala universitet, Institutionen för biologisk grundutbildning, Uppsala universitet, Institutionen för immunologi, genetik och patologi |
| Source Sets | DiVA Archive at Upsalla University |
| Language | English |
| Detected Language | English |
| Type | Student thesis, info:eu-repo/semantics/bachelorThesis, text |
| Format | application/pdf |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0018 seconds